Genentech's Tecentriq-Avastin Combo Approved for HCC, an Improvement on Standard of Care

Press/Media

Period	1 Jun 2020

Media coverage

Title	Genentech's Tecentriq-Avastin Combo Approved for HCC, an Improvement on Standard of Care
Media name/outlet	BioSpace
Country/Territory	United States
Date	1/06/20
URL	https://www.biospace.com/article/genentech-s-avastin-tecentriq-combination-gets-greenlight-for-liver-cancer/
Persons	Josep Llovet